PlainPharmaWatch

CMS Open Payments · Program Year 2024

Ascend Therapeutics US, LLC

Ascend Therapeutics US, LLC reported $74,588.40 across General Payments, Research, and Ownership to 282 physicians and teaching hospitals across 282 transactions.

$74.6K
All-tracks total
282
Transactions
282
Recipients
+$27.5K
General Payments vs PY2023

Ascend Therapeutics US, LLC reported $74,588.40 across all CMS Open Payments tracks (General + Research + Ownership) to 282 physicians and teaching hospitals in Program Year 2024 - ranking #1258 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $74,588.40, averaging $264.50 per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

CMS Sunshine Act warrant

Manufacturer ascend-therapeutics-us-llc Ascend Therapeutics US, LLC

$74.6K · #1258/1,925 · 0.0% industry · PY2024

  • TOT $74.6K
  • RANK #1258
  • SHARE 0.0%
  • TXN 282
  • RCP 282
  • CAT 5
  • GEN $74.6K
  • ΔGEN +$27.5K
  • TOP1 24.8%
  • PY 2024

Nearest volume peer: Aspira Women's Health Inc ($74.7K)

Pinnacle Biologics, Inc$75.4KEvolution Surgical, Inc$74.8KAspira Women's Health Inc$74.7KAscend Therapeutics US, LLC …$74.6KLightbody Medical Technologi…$74.3K
All-tracks payment totals near Ascend Therapeutics US, LLC (CMS Open Payments PY2024)

Ascend Therapeutics US, LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Ascend Therapeutics US, LLC's CMS-reported General Payments increased by $27.5K (+58.3%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: ASCEND THERAPEUTICS US, LLCPY2023: ASCEND THERAPEUTICS US, LLCPY2024: ASCEND THERAPEUTICS US, LLC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$47.1KPY2024$74.6K
PY2023
$47,129.64
PY2024
$74,588.40

What the Data Shows for Ascend Therapeutics US, LLC

$74,588.40: that is what Ascend Therapeutics US, LLC reported in payments to 282 physicians and teaching hospitals during Program Year 2024, spread across 282 transactions ($264.50 per transaction, $264.50 per recipient). The company sits at rank #1258 of 1,925, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

24 transactions worth $59.6K make "Consulting Fee" the top general-payment category in the 5-category breakdown below, 79.9% of General Payments (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

"Consulting Fee" leads Ascend Therapeutics US, LLC's 5-category general-payment breakdown at $59.6K, 79.9% of the reported total.

Ascend Therapeutics US, LLC reports 5 general-payment categories - the top three are Consulting Fee (79.9%), Honoraria (14.1%), and Food and Beverage (5.9%). The remaining 2 categories make up 0.2% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.

How Ascend Therapeutics US, LLC divides its payments

Top payment categories by total reported dollar volume

1. Consulting Fee$59.6K2. Honoraria$10.5K3. Food and Beverage$4.4K4. Travel and Lodging$87.055. Gift$46.10
Payment Type Amount Transactions
Consulting Fee $59.6K 24
Honoraria $10.5K 7
Food and Beverage $4.4K 228
Travel and Lodging $87.05 1
Gift $46.10 22

Recipient Concentration in General Payments

The five largest recipient relationships account for $57,685.55 (77.3%) of $74,588.40 in this company's General Payments records across 222 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Ascend Therapeutics US, LLC

The five named recipients with the highest reported General Payments from this company

Stephen Rabin$18.5KElliot Cazes$13.0KMaureen Whelihan$13.0KJames Alan Simon$10.2KParveen Vahora$3.0K
  1. 1

    Stephen Rabin

    $18,504.95 across 7 reported transactions

  2. 2

    Elliot Cazes

    $13,002.80 across 12 reported transactions

  3. 3

    Maureen Whelihan

    $13,000.90 across 7 reported transactions

  4. 4

    James Alan Simon

    $10,174.10 across 7 reported transactions

  5. 5

    Parveen Vahora

    $3,002.80 across 10 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Ascend Therapeutics US, LLC's, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Ascend Therapeutics US, LLC.

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Ascend Therapeutics US, LLC.

Showing 6 of 1,924 companies with CMS-reported payment data.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

View saved (companies)
Download Ascend Therapeutics US, LLC's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.